The metabolism of psychoactive drugs: A review of enzymatic biotransformation and inhibition

Biological Psychiatry

Volumn 41, Issue 7, 1997, Pages 814-826

  Shen, Winston W ^a,b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Anticancer; Antidepressants; Antipsychotic drugs (major tranquilizers); Benzodiazepines (minor tranquilizers); Biotransformation; Cytochrome P450s; Enzymatic bioactivation; Enzymatic inhibition; Hepatotoxicity; Human; Mood stabilizing agents; Substances of abuse; Tacrine

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CHLORPROMAZINE; CITALOPRAM; CLORAZEPATE; CYTOCHROME P450; DESIPRAMINE; DIAZEPAM; FLUOXETINE; FLUVOXAMINE; HALOZEPAM; IMIPRAMINE; MOCLOBEMIDE; NOOTROPIC AGENT; NORTRIPTYLINE; PAROXETINE; PRAZEPAM; PSYCHOTROPIC AGENT; SERTRALINE; UNCLASSIFIED DRUG; VENLAFAXINE;

BIOTRANSFORMATION; DRUG ABUSE; DRUG METABOLISM; HUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; HEPATITIS, TOXIC; HUMANS; LIVER; METABOLIC DETOXICATION, DRUG; PSYCHOTROPIC DRUGS;

EID: 0030975675     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(96)00180-1     Document Type: Review

References (112)

1. Ackenheil M (1989): Clozapine: Pharmacokinetic investigations and biochemical effects. Psychopharmacology 99:532-537.
2. Anderson T, Miners JO, Veronese ME, Birkett DJ (1994): Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP A3A isoforms. Br J Clin Pharmacol 38:131-137.
3. Balian JD, Sukhova N, Harris JW, et al (1995): The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study. Clin Pharmacol Ther 57:662-669.
4. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Säwe J, Villén T (1989): Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S-mephenyton, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 45:348-355.
5. Bertilsson L, Carrillo JA, Dahl M-L, et al (1994): Clozapine disposition covaries with CYP 1A2 activity determined by a caffeine test. Br J Clin Pharmacol 38:471-473.
6. Blake BL, Rose RL, Mailman RB, Levi PE, Hodgson E (1995): Metabolism of thioridazine by microsomal monooxygenases: Relative roles of P450 and flavin-containing monooxygenase. Xenobiotica 25:377-393.
7. Boelsterli UA, Atanasoski S, Goldlin C (1991): Ethanol-induced enhancement of cocaine bioactivation and irreversible protein binding: Evidence against a role of cytochrome P450IIE1. Alcohol Clin Exp Res 15:779-784.
8. Boelsterli US, Lanzotti A, Gölding C, Oertle M (1992): Identification of cytochrome P450 IIBI as a cocaine-bioactivating isoform in rat hepatic microsomes and in cultured rat hepatocytes. Drug Metab Dispos 20:96-101.
9. Bolvig-Hansen L, Elley J, Rosted CT, Larsen NE, Naestoft J, Hvidberg EF (1979): Plasma levels of perphenazine and its major metabolites during simultaneous treatment with anticholinergic drugs. Br J Clin Pharmacol 7:75-80.
10. Boomer JC, Woods FR, Haddock RE, Lennard MS, Tucker GT (1992): The role of cytochrome P450 2D6 in the metabolism of paroxetine by human liver microsomers. Br J Clin Pharmacol 33:521-523.
11. Brain WR, Srivastava PK, Umbenhauer DR, Lloyd RS, Guengerich FP (1989): Expression of a human liver cytochrome P450 protein with tolbutamide hydroxylase activity in saccharomyces cerevisiae. Biochemistry 28:4993-4999.
12. Brewster D, Muri NC (1980): Valproate plasma protein binding in the uremic condition. Clin Pharmacol Ther 27:76-82.
13. Breyer-Pfaff U, Pfandl B, Nill K, et al (1992): Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isoenzymes. Clin Pharmacol Ther 52:350-358.
14. Brösen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loff S (1993): Fluvoxamine is a potent inhibitor of cytochrome P450 1A2. Biochem Pharmacol 45:1211-1214.
15. Carry PV, Ducluzeau R, Jourdan C, Bourrat C, Vigneau C, Descotes J (1982): De nouvelles interactions avec les macrolides (New interactions with macrolides). Lyon Med 248:189-190.
16. Claassen V (1983): Review of the animal pharmacology and pharmacokinetics of fluvoxamine. Br J Clin Pharmacol 15:349S-355S.
17. Dahl-Puustinen M-L, Lidén A, Alm C, Nordin C, Bertilsson L (1989): Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther 46:78-81.
18. Eichelbaum M, Tomson T, Tybring G, Bertilsson L (1985): Carbamazepine metabolism in man: Induction and pharmacogenetic aspects. Clin Pharmacokinet 10:80-90.
19. Fang J, Yu PH, Gorrod JW, Boulton AA (1995): Inhibition of monoamine oxidases by haloperidol and its metabolites: Pharmacological implications for the chemotherapy of schizophrenia. Psychopharmacology 118:206-212.
20. Fischer V, Vogels B, Maurer G, Tynes RE (1992): The antipsychotic clozapineis metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J Pharmacol Exp Ther 260:1355-1360.
21. Gauch R, Michaelis W (1971): The metabolism of 8-chloro-11-(4-methyl-1-piperzinyl)-5H-dibenzo (b, e) (1, 4) diazepine (clozapine) in mice, dogs and human subjects. Farming Ed Pract 26:667-681.
22. Gram LF, Guentert TW, Grange S, Vistisen K, Brøsen K (1995): Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6 and CYP1A2: A panel study. Clin Pharmacol Ther 57:670-677.
23. Greenblatt DJ, Allen MD, Lokniskar A, Harmatz JS, Shader RI (1979): Lorazepam kinetics in the elderly. Clin Pharmacol Ther 26:103-113.
24. Gu L, Gonzalez FJ, Kalow W, Tang BK (1992): Biotransformation of caffeine, paraxanthine, theobromine, and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 2:73-77.
25. Guengerich FP, Turvy CG (1991): Comparison of levels of several human microsomal cytochrome P450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Exp Pharmacol Ther 256:1189-1194.
26. Haddock RE, Johnson AM, Langley PF, et al (1989): Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites. Acta Psychiatr Scand 80(suppl 350):24-26.
27. Halpert JR, Guengerich FP, Bend JR, Correia MA (1994): Contemporary issues in toxicology: Selective inhibitors of cytochrome P450. Toxicol Appl Pharmacol 125:163-175.
28. Hamberg O, Ovesen L, Dorfeldt A, Loft S, Sonne J (1990): The effect of dietary energy and protein deficiency on drug metabolism. Eur J Clin Pharmacol 38:567-570.
29. Hoag MKP, Trevor AJ, Kalir A, Castragnoli N Jr (1987): Phenocyclidine iminium ion NADPH-dependent metabolism, covalent binding to macromolecules and inactivation of cytochrome(s) P450. Drug Metab Dispos 15:485-490.
30. Honkakoski P, Auriola S, Lang MA (1992a): Distinct induction profiles of three phenobarbital-responsive mouse liver cytochrome P450 isozymes. Biochem Pharmacol 43:2121-2128.
31. Honkakoski P, Kojo A, Lang MA (1992b): Regulation of mouse liver cytochrome P450 subfamily 2B by sex hormones and phenobarbital. Biochem J 285:979-983.
32. Huang M-L, van Peer A, Woestenborghs R, et al (1993): Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 54:257-268.
33. Ingelman-Sundberg M, Johansson I, Yin H, et al (1993): Ethanol-inducible cytochrome P450 2E1: Genetic polymorphism, regulation and possible role in the etiology of alcohol-induced liver disease. Alcohol 10:447-452.
34. Ishikawa M, Aoki T, Yomogida S, Takayanagi Y, Sasaki K-I (1994): Drug interaction effects on antitumor drugs (XV): Disulfiram as protective agent against cyclophosphamide-induced urotoxicity without compromising antitumor activity in mice. Pharmacol Toxicol 74:255-261.
35. Jerling M, Lindström, Bondesson U, Bertilsson L (1994): Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: Evidence from a therapeutic drug monitoring service. Ther Drug Monit 16:368-374.
36. Jørgensen A (1986): Metabolism and pharmacokinetics of antipsychotic drugs. In Bridges JW, Chasseaud LF (eds), Progress in Drug Metabolism, Vol 9. London: Taylor and Francis, pp 111-174.
37. Kanel GC, Cassidy W, Shuster L, Reynolds TB (1990): Cocaine-induced liver cell injury: Comparison of morphological features in man and in experimental models. Hepatology 11: 646-651.
38. Kerr BM, Rettie AE, Eddy AC, et al (1989): Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: In vitro/in vivo correlation. Clin Pharmacol Ther 46:82-93.
39. Kharasch ED, Thummel KE, Maulz D, Bosse S (1994): Clinical enflurane metabolism by cytochrome P450 2E1. Clin Pharmacol Ther 55:434-440.
40. Kilbane AJ, Silbart LK, Manis M, Beitins IZ, Weber WW (1990): Human N-acetylation genotype determination with urinary caffeine metabolites. Clin Pharmacol Ther 47:470-477.
41. Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST (1992): Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its O-demethyl metabolite. J Clin Pharmacol 32:716-724.
42. Knodell RG, Dubey PK, Wilkinson GR, Guergerich FP (1988): Oxidative metabolism of hexobarbital in human liver: Relationship to polymorphic S-mephenytoin 4-hydroxylation. J Pharmacol Exp Ther 245:845-849.
43. Knodell RG, Browne DB, Gwozdz GP, Brian WR, Guengerich FP (1991): Differential inhibition of individual human liver cytochromes P-450 by cimetidine. Gastroenterology 101: 1680-1691.
44. Kobayashi K, Yamamoto T, Chiba K, Tani M, Ishizaki T, Kuroiwa Y (1996): The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4 hydroxylase activity in human liver microsomes. Br J Clin Pharmacol 40:481-485.
45. Kostrubsky VE, Strom SC, Wood SG, Wrighton SA, Sinclair PR, Sinclair JF (1995): Ethanol and isopentanol increase CYP3A and CYP2E in primary cultures of human hepatocytes. Arch Biochem Biophys 322:516-520.
46. Koymans L, Vermuelen NPE, van Acker SABE, et al (1992): A predictive model for substrates of cytochrome P45-debrisoquine (2D6). Chem Res Toxicol 5:211-219.
47. Kroemer HK, Klotz U (1992): Glucuronidation of drugs: A re-evaluation of pharmacological significance of the conjugates and modulating factors. Clin Pharmacokinet 23:292-310.
48. Kronbach T, Mathys D, Umeno M, Gonzales FJ, Meyer UA (1989): Oxidation of midazolam and triazolam by human liver cytochrome P450 IIIA4. Mol Pharmacol 36:89-96.
49. Küpfer A, Desmond P, Patwardhan R, Schenker S, Branch RA (1984): Mephenytoin hydroxylation deficiency: Kinetics after repeated doses. Clin Pharmacol Ther 35:33-39.
50. Lasker JM, Raucy J, Kubota S, Bloswick BP, Black M, Lieber CS (1987): Purification and characterization of human liver cytochrome P450 ALC. Biochem Biophy Res Commun 148: 232-238.
51. Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF (1988): The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther 43:412-419.
52. Lemoine A, Gautier JC, Azoulay D, et al (1993): Major pathway of imipramine metabolism catalyzed by cytochromes P450 1A2 and P450 3A4 in human liver. Mol Pharmacol 45:827-832.
53. Lertratanangkoon K, Horning MC (1981): Metabolism of carbamazepine. Drug Metab Dispos 10:1-10.
54. Lieber CS (1994): Mechanisms of ethanol-drug-nutrition interactions. Clin Toxicol 32:631-681.
55. Lieber CS, Decarli LM (1968): Ethanol oxidation by hepatic microsomes: Adaptive increase after ethanol feeding. Science 162:917-918.
56. Lin KM, Poland RE (1995): Ethnicity, culture and psychopharmacology. In Bloom FE, Kupfer DJ (eds), Psychopharmacology; The Fourth Generation of Progress. New York: Raven Press, pp 1907-1917.
57. Llerena A, Aim C, Dahl M-L, Ekqvist B, Bertilsson L (1992a): Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 14:92-97.
58. Llerena A, Dah M-L, Ekqvist B, Bertilsson L (1992b): Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: Increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit 14:261-264.
59. Lu AYH, Coon MJ (1968): Role of hemoprotein P450 in fatty acid ω-hydroxylation in a soluble enzyme system from liver microsomes. J Biol Chem 243:1331-1332.
60. Madden S, Woolf TF, Pool WF, Park BK (1993): An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro: Studies with human and rat liver microsomers. Biochem Pharmacol 46:13-20.
61. Madden S, Spaldin V, Park BK (1995): Clinical pharmacokinetics of tacrine. Clin Pharmacokinet 28:449-457.
62. Mannens G, Huang ML, Meuldermans J, Hendrickx R, Woestenborghs Heykant J (1993): Absorption metabolism and excretion of risperidone in humans. Drug Metab Dispos 21:1134-1143.
63. Mellström B, Sawe J, Bertilsson L, Sjoquist F (1986): Amitriptyline metabolism: Association with debrisoquin hydroxylation in non-smokers. Clin Pharmacol Ther 39:369-371.
64. Meuldermans W, Hendricks J, Mannens G, et al (1994): The mechanism and excretion of risperidone after oral administration in rats and dogs. Drug Metab Dispos 22:129-138.
65. Miles JS, McLaren AW, Forrester LM, Glancey MJ, Lang MA, Wolf CR (1990): Identification of the human liver cytochrome P450 responsible for coumarin 7-hydroxylase activity. Biochem J 267:365-371.
66. Muth EA, Haskins JT, Moyer JA, Husbands GEM, Nielsen ST, Sigg EB (1986): Antidepressant biochemical profile of the novel bicyclic compounds Wy-45,030: An ethyl cyclohexanol derivative. Biochem Pharmacol 35:4493-4497.
67. Muth EA, Moyer JA, Haskins JT, Andree TH, Husbands GEM (1991): Biochemical, neurophysiological and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 23:191-199.
68. Nelson SD (1990): Molecular mechanisms of the hepatotoxicity caused by acetaminophen. Sem Liver Dis 10:267-278.
69. Nelson DR, Kamataki T, Waxman DI, et al (1993): The P450 superfamily: Update on sequences, gene mapping, accession numbers, early trivial names of enzymes and nomenclature. DNA Cell Biol 12:1-51.
70. Nordin C, Bertilsson L (1995): Active hydroxymetabolites of antidepressants: Emphasis on E-10-hydroxy-nortriptyline. Clin Pharamcokinet 28:26-40.
71. Nyth AL, Gottfries CG (1990): The clinical efficacy of citalopram in the treatment of emotional disturbances of dementic disorders. Br J Psychiatry 157:894-901.
72. O'Brien JT, Eagger S, Levy R (1991): Effects of tetrahydroaminoacrine on liver function in patients with Alzheimer's disease. Age Aging 20:129-131.
73. Olkkola KT, Aranko K, Luurila H, et al (1993): A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 53:298-305.
74. Osawa Y, Coon MJ (1989): Selective mechanism-based inactivation of the major phenobarbital-inducible P450 cytochrome from rabbit liver by phencyclidine and its oxidation product, the iminium compound. Drug Metab Dispos 17:7-13.
75. O'Shea D, Davis SN, Kim RB, Wilkinson GR (1994): Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: A putative probe of CYP2E1 activity. Clin Pharmacol Ther 56:359-367.
76. Patwarhan RV, Yarborough GW, Desmond PV, Johnson RF, Schenker S, Speeg KV Jr (1980): Cimetidine spares the glucuronidatin of lorazepam and oxazepam. Gastroenterology 79:912-916.
77. Peck CC, Temple R, Collins JM (1993): Understanding consequences of concurrent therapies. JAMA 269:1550-1552.
78. Pellinen P, Honkakoski P, Stenbäck F, et al (1994): Cocaine N-demethylation and metabolism-related hepatotoxicity can be prevented by cytochrome P450 3A inhibitors. Eur J Pharmacol 270:35-43.
79. Pentikäinen, Välisalmi L, Himberg JJ, Crevoisier C (1989): Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol 29:272-277.
80. Phillips JP, Antal EJ, Smith RB (1986): A pharmacokinetic drug interaction between erythromycin and trizolam. J Clin Psychopharmacol 6:297-299.
81. Pirmohamed M, Williams D, Madden S, Templeton E, Park BK (1995): Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 272:984-990.
82. Poet TS, McQueen CA, Halpert JR (1996): Participation of cytochromes P450 2B and P450 3A in cocaine toxicity in rat hepatocytes. Drug Metab Dispos 24:74-80.
83. Pollock BG (1994): Recent developments in drug metabolism of relevance to psychiatrists. Harvard Rev Psychiatry 2:204-213.
84. Pollock BG, Perel JM, Kirshner M, Altieri L, Yeager A, Reynolds CF (1991): Mephenytoin 4-hydroxylation in older Americans. Eur J Clin Pharmacol 40:609-611.
85. Potter WZ, Calid HM, Manian AA, Zavadil AP, Goodwin FK (1979): Hydroxylated metabolites of tricyclic antidepressants: Preclinical assessment of activity. Biol Psychiatry 14:601-613.
86. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S (1994): Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psycholpharmacol 14:90-98.
87. Robin DW, Lee MH, Hasan SS, Wood AJJ (1993): Triazalm in cirrhosis: Pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 54:630-637.
88. Rost KL, Roots I (1994): Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolic ratios: Coincidence with plasma clearance and breath test. Clin Pharmacol Ther 55:402-411.
89. Ruckpaul K, Rein H (eds) (1990): Principles, Mechanisms and Biological Consequences of Induction. London: Taylor & Francis.
90. Sanz EJ, Bertilsson L (1990): d-Propoxyphene is a potent inhibitor of debrisoquine, but not S-mephenytoin 4-hydroxylation in vivo. Ther Drug Monit 12:297-299.
91. Shen WW (1995): Cytochrome P450 monooxygenases and interactions of psychotropic drugs: A five-year update. Int J Psychiatry Med 25:277-290.
92. Shen WW, Lin K-M (1991): Cytochrome P450 monooxygenases and interactions of psychotropic drugs. Int J Psychiatry Med 21:47-56.
93. Siegmund W, Hanke W, Zschiesche M, Franke G, Biebler KE, Wilke A (1990): N-acetylation and debrisoquin type oxidation polymorphism in Caucasians with reference to age and sex. Int J Clin Pharmacol Ther Toxicol 28:504-509.
94. Sindrup SH, Brosen K, Gram LF (1992a): Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 51:288-295.
95. Sindrup SH, Brøsen K, Gram LF, et al (1992b): The relationship between paroxetine and sparteine oxidation polymorphism. Clin Pharmacol Ther 51:278-287.
96. Skjelbo E, Brøsen K, Hallas J, Gram LF (1991): The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharamcol Ther 49: 18-23.
97. Spaldin V, Madden S, Pool WF, Woolf TF, Park BK (1994): The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes. Br J Clin Pharmacol 38:15-22.
98. Spina E, Campo GM, Avenoso A, Pollicino MA, Caputi AP (1992): Interaction between fluvoxamine and imipramine/ desipramine in four patients. Ther Drug Monit 14:194-196.
99. Spinier SA, Cheng JWM, Kindwall KE, Charland SL (1995): Possible inhibition of hepatic metabolism of quinidine by erythromycin. Clin Pharmacol Ther 57:89-94.
100. Srivastava PK, Yun C-H, Beaune PH, Ged C, Guengerich FP (1991): Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4-hydroxylase cytochrome P450 enzymes. Mol Pharmacol 40:69-79.
101. 3 groups in metabolizing clozapine in human organisms. Arzneimische Forschrift 27:982-990.
102. Tollefson GD (1981): Delirium induced by the competitiveness interaction between phenytoin and diproplyacetote. J Clin Psychopharmacol 1:154-158.
103. Tyndale R, Kalow W, Inaba T (1991): Oxidation of reduced haloperidol to haloperidol: Involvement of human P450 IID6 (sparteine/debrisoquine monooxygenase). Br J Clin Pharmacol 31:650-655.
104. vanden Bosche H (1992): Inhibitors of P450-dependent steroid synthesis: From research to medical treatment. J Steroid Biochem Mol Biol 8:1003-1021.
105. Van Wauwe JP, Janssen PAJ (1989): Is there a case for P-450 inhibitors in cancer treatment? J Med Chem 32:2331-2239.
106. Varhe A, Olkkola KT, Neuvonen PJ (1994): Oral trizolam is potentially hazardous to patients receiving systematic antimycotics, ketoconazole or itraconazole. Clin Pharmacol Ther 56:601-607.
107. von Bahr C, Movin G, Nordin C, et al (1991): Plasma levels of thioridazine and metabolites are influenced by the debrisoquine hydroxylation phenotype. Clin Pharmacol Ther 49: 234-240.
108. Watkins PB (1992): Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol Clin North Am 21:511-526.
109. Wieholt H, Zysset TH, Kreiten K, Kohl D, Büchsel R, Matern S (1989): Effect of phenytoin, calbamazepine and valpric acid on caffeine metabolism. Eur J Clin Pharmacol 36:401-406.
110. Young RC, Alexopoulos GS, Shamoian CA, Kent E, Dhar AK, Kutt H (1985): Plasma 10-hydroxynortriptyline and ECG changes in elderly depressed patients. Am J Psychiatry 142:866-868.
111. Yue QY, Svensson JO, Aim C, Sjöqvist F, Säwe J (1989): Codeine O-demethylation consegregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol 28:639-645.
112. Zhou H, Wood AJJ (1991): The stereoselective inhibition of propranolol metabolism by quinidine is phenotype dependent. Clin Res 39:264-266.